Stephen Feider Sells 6,675 Shares of Beta Bionics (NASDAQ:BBNX) Stock

Beta Bionics, Inc. (NASDAQ:BBNX) CFO Stephen Feider sold 6,675 shares of the business’s stock in a transaction dated Wednesday, September 2nd. The shares were sold at an average price of $19.11, for a total transaction of $127,559.25. Following the completion of the sale, the chief financial officer directly owned 159,378 shares of the company’s stock, valued at approximately $3,045,713.58. The trade was a 4.02% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Stephen Feider also recently made the following trade(s):

• On Monday, June 29th, Stephen Feider sold 4,896 shares of Beta Bionics stock. The shares were sold at an average price of $17.03, for a total transaction of $83,378.88.
• On Friday, June 26th, Stephen Feider sold 5,104 shares of Beta Bionics stock. The stock was sold at an average price of $17.05, for a total transaction of $87,023.20.

Beta Bionics Trading Down 2.5%

NASDAQ BBNX opened at $19.42 on Friday. The company has a market cap of $873.71 million, a price-to-earnings ratio of -11.77 and a beta of 3.37. The company has a 50 day moving average of $17.17 and a 200-day moving average of $13.65. Beta Bionics, Inc. has a 1-year low of $8.80 and a 1-year high of $32.71.

Beta Bionics (NASDAQ:BBNX) last issued its quarterly earnings results on Wednesday, July 29th. The company reported ($0.53) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.62) by $0.09. Beta Bionics had a negative return on equity of 26.30% and a negative net margin of 61.31%.The business had revenue of $32.01 million for the quarter. On average, equities research analysts forecast that Beta Bionics, Inc. will post -2.1 earnings per share for the current year.

Analyst Ratings Changes

A number of research analysts recently commented on the company. Truist Financial boosted their price target on Beta Bionics from $18.00 to $22.00 and gave the company a “buy” rating in a research note on Monday, July 13th. Bank of America reduced their price target on shares of Beta Bionics from $23.00 to $11.00 and set a “neutral” rating on the stock in a research report on Monday, May 18th. The Goldman Sachs Group lifted their price target on Beta Bionics from $17.00 to $19.00 and gave the company a “buy” rating in a research note on Wednesday, July 15th. UBS Group started coverage on Beta Bionics in a research note on Tuesday, July 28th. They set a “buy” rating and a $22.00 target price for the company. Finally, Weiss Ratings raised shares of Beta Bionics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Tuesday, August 18th. Seven investment analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $20.10.

Beta Bionics News Summary

Here are the key news stories impacting Beta Bionics this week:

• Positive Sentiment: Analyst sentiment remains favorable overall, with seven Buy ratings, four Holds and one Sell, producing a “Moderate Buy” consensus and an average price target of $20.10. Recent institutional purchases, including a new position by Bank of America valued at approximately $8.6 million, also provide some support. Beta Bionics insider trading and analyst coverage
• Neutral Sentiment: Several Beta Bionics insiders—including CFO Stephen Feider, Steven Russell, Mike Mensinger and Mark Hopman—sold shares at approximately $19.11 each. The transactions collectively involved about 20,600 shares, but the filings state the sales were made to cover tax-withholding obligations tied to vested equity awards, reducing their significance as a discretionary bearish signal. Beta Bionics insider sales
• Negative Sentiment: Schall, Brown & Schwartz LLP announced that it has filed a class-action lawsuit against Beta Bionics and is seeking investors to serve as lead plaintiffs. The litigation introduces potential legal costs, reputational risk and uncertainty regarding the company’s disclosures or conduct, creating the most significant near-term pressure on BBNX. The allegations have not been adjudicated. BBNX investor alert and class-action lawsuit

Institutional Trading of Beta Bionics

Institutional investors and hedge funds have recently bought and sold shares of the stock. Strs Ohio acquired a new stake in shares of Beta Bionics in the first quarter valued at about $29,000. Summit Securities Group LLC acquired a new position in shares of Beta Bionics in the fourth quarter worth approximately $52,000. Legal & General Group Plc boosted its holdings in Beta Bionics by 197.4% in the second quarter. Legal & General Group Plc now owns 3,976 shares of the company’s stock valued at $58,000 after acquiring an additional 2,639 shares during the last quarter. Caitong International Asset Management Co. Ltd boosted its holdings in Beta Bionics by 1,075.7% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 1,987 shares of the company’s stock valued at $61,000 after acquiring an additional 1,818 shares during the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new stake in Beta Bionics during the 1st quarter valued at approximately $95,000.

Beta Bionics Company Profile

Beta Bionics, a clinical-stage medical device company headquartered in Boston, Massachusetts, is focused on revolutionizing the management of type 1 diabetes through automated insulin delivery solutions. The company’s flagship product, the iLet Bionic Pancreas system, is designed to simplify glycemic control by automatically adjusting insulin dosing in response to continuous glucose monitoring data. By integrating advanced algorithmic control with wearable infusion pumps, the iLet aims to reduce the daily burden of diabetes management and improve clinical outcomes for patients.

At the core of Beta Bionics’ offering is its proprietary bionic pancreas software, which can operate in both insulin-only and dual‐hormone modes.